Advertisement

Evaluation of In Vivo Natural Killer and Lymphokine-Activated Killer Cell Activity in Patients Treated with High-Dose Interleukin-2 and Adoptive Transfer of Autologous LAK Cells

  • J. Walewski
  • E. Paietta
  • J. Dutcher
  • P. H. Wiernik
Conference paper

Abstract

A substantial number of Phase I and Phase II clinical trials of interleukin-2 (IL-2) alone or combined with adoptive transfer of lymphokine-activated killer (LAK) cells in the treatment of cancer patients had defined IL-2 pharmacokinetics in humans, some immunodulatory effects, toxicity and maximum tolerated doses, and a preliminary evaluation of antitumor activity of this novel approach to therapy [2, 3].

Keywords

Natural Killer Natural Killer Cell Activity Natural Killer Activity Lytic Unit Blood Sampie 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hank JA, Kohler PC, Weil-Hillman G, Rosenthal N, Moore KH, Storer B, Minkoff D, Bradshaw J, Bechhofer R, Sodel PM (1988) In vivo induction of the lymphokine-activated killer phenomenon:interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2. Cancer Res 48:1965–1971PubMedGoogle Scholar
  2. 2.
    Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SD, Seipp CAY, Custer MC, Rosenberg SA (1985) In vivo administration of purified human interleukin 2, II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2, J Immunol 135:2865–2875PubMedGoogle Scholar
  3. 3.
    McMannis JD, Fisher RI, Creekmore SP, Braun DP, Harris JE, Ellis TM (1988) In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2, J Immunol 140:1335–1340PubMedGoogle Scholar
  4. 4.
    Phillips JH, Gemlo BT, Myers WW, Rayner AA, Lanier LL (1987) In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined interleukin 2 and LAK cell therapy. J Clin Oncol 5:1933–1941PubMedGoogle Scholar
  5. 5.
    Pross HF, Maroun JA (1984) The standardization of NK cell assays for use in studies of biological response modifiers. J Immunol Methods 68:235–249PubMedCrossRefGoogle Scholar
  6. 6.
    Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Levitt D, Fefer A (1988) Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 6:669–678PubMedGoogle Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1990

Authors and Affiliations

  • J. Walewski
  • E. Paietta
  • J. Dutcher
  • P. H. Wiernik

There are no affiliations available

Personalised recommendations